Orion S.A.OECEarnings & Financial Report
Orion Corporation, founded in 1917 and headquartered at Espoo, Finland, is a globally operating Finnish company which develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients for global markets. All of the company's manufacturing sites and the majority of its R&D units are in Finland.
Revenue
$434.2M
Gross Profit
$89.3M
Operating Profit
$23.6M
Net Profit
N/A
Gross Margin
20.6%
Operating Margin
5.4%
Net Margin
N/A
YoY Growth
-7.3%
EPS
$0.31
Orion S.A. Q4 FY2024 Financial Summary
Orion S.A. reported revenue of $434.2M (down 7.3% YoY) for Q4 FY2024, with a net profit of N/A (N/A margin). Cost of goods sold was $344.9M, operating expenses totaled $65.7M.
Key Financial Metrics
| Total Revenue | $434.2M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 20.6% |
| Operating Margin | 5.4% |
| Report Period | Q4 FY2024 |
Revenue Breakdown
Orion S.A. Q4 FY2024 revenue of $434.2M breaks down across 2 segments, led by Rubber at $286.8M (66.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Rubber | $286.8M | 66.1% |
| Specialties | $147.4M | 33.9% |
Orion S.A. Revenue by Segment — Quarterly Trend
Orion S.A. revenue by segment across the last 4 reported quarters, showing how each business line (such as Rubber and Specialties) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Rubber | — | $272.0M | $290.9M | $308.3M |
| Specialties | — | $139.7M | $160.0M | $158.1M |
Orion S.A. Annual Revenue by Year
Orion S.A. annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.8B).
| Year | Annual Revenue |
|---|---|
| 2025 | $1.8B |
| 2024 | $1.9B |
| 2023 | $1.9B |
| 2022 | $2.0B |
Orion S.A. Quarterly Revenue & Net Profit History
Orion S.A. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $459.5M | -3.8% | $-9.9M | -2.2% |
| Q4 FY2025 | $411.7M | -5.2% | N/A | N/A |
| Q3 FY2025 | $450.9M | -2.7% | $-67.1M | -14.9% |
| Q2 FY2025 | $466.4M | -2.2% | $9.0M | 1.9% |
| Q1 FY2025 | $477.7M | -5.0% | $9.1M | 1.9% |
| Q4 FY2024 | $434.2M | -7.3% | N/A | N/A |
| Q3 FY2024 | $463.4M | -0.6% | $-20.2M | -4.4% |
| Q2 FY2024 | $477.0M | +4.0% | $20.5M | 4.3% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $477.0M | $463.4M | $434.2M | $477.7M | $466.4M | $450.9M | $411.7M | $459.5M |
| YoY Growth | 4.0% | -0.6% | -7.3% | -5.0% | -2.2% | -2.7% | -5.2% | -3.8% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.91B | $2.00B | $1.86B | $1.97B | $2.02B | $1.96B | $1.91B | $1.93B |
| Liabilities | $1.40B | $1.52B | $1.38B | $1.50B | $1.56B | $1.56B | $1.52B | $1.55B |
| Equity | $503.9M | $476.3M | $474.9M | $466.1M | $466.5M | $401.8M | $384.6M | $379.5M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $29.3M | $-30.9M | $94.5M | $400000 | $53.7M | $68.8M | $92.9M | $-12.4M |